References
- 1. TINETTI ME, BOGARDUS ST, AGOSTINI JV. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N Engl J Med. 2004; 351(27):2870–2874.
- 2. GANDHI TK, WEINGART SN, BORUS J, SEGER AC, PETERSON J, BURDICK E, et al. Adverse drug events in ambulatory care. N Engl J Med. 2003; 348(16):1556–1564.
- 3. KANTOR ED, REHM CD, HAAS JS, CHAN AT, GIOVANUCCI EL. Trends in prescription drug use among adults in the United States from 1999–2012. Jama. 2015; 314(17):1818–1831.
- 4. EVERHART JE, RUHL CE. Burden of digestive diseases in the United States part I: overall and upper gastrointestinal diseases. Gastroenterology. 2009; 136(2):376–386.
- 5. IMHANN F, BONDER MJ, VILA AV, FU J, MUJAGIC Z, VORK L, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016; 65(5):740–748.
- 6. SPIEGEL BM, CHEY WD, CHANG L. Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors? Am J Gastroenterol. 2008; 103(12):2972–2976.
- 7. HOLZER P. Treatment of opioid-induced gut dysfunction. Expert Opin Investig Drugs. 2007; 16(2):181–194.
- 8. LACY BE. Effects of Opioids on Esophageal Dysfunction. Gastroenterol Hepatol (N Y). 2016; 12(5):323–325.
- 9. CAMILLERI M, LEMBO A, KATZKA DA. Opioids in Gastroenterology: Treating Adverse Effects and Creating Therapeutic Benefits. Clin Gastroenterol Hepatol. 2017; 15(9):1338–1349.
- 10. CHIAL HJ, CAMILLERI M, BURTON D, THOMFORDE G, OLDEN KW, STEPHENS D. Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health. Am J Physiol Gastrointest Liver Physiol. 2003; 284(1):G130–137.
- 11. HALPERT A, DALTON CB, DIAMANT NE, TONER BB, HU Y, MORRIS CB, et al. Clinical response to tricyclic antidepressants in functional bowel disorders is not related to dosage. Am J Gastroenterol. 2005; 100(3):664–671.
- 12. ZHONG W, MARADIT-KREMERS H, ST AUVER JL, YAWN BP, EBBERT JO, ROGER VL, et al. Age and sex patterns of drug prescribing in a defined American population. Mayo Clin Proc. 2013; 88(7):697–707.
- 13. FRANSSEN FM, SPRUIT MA, WOUTERS EF. Determinants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2011; 6:493–501.
- 14. HOFFMAN F, VAN DES BUSSCHE H, WIESE B, SCHON G, KOLLER D, EISELE M, et al. Impact of geriatric comorbidity and polypharmacy on cholinesterase inhibitors prescribing in dementia. BMC Psychiatry. 2011; 11:190.
- 15. PATEL PJ, HAYWARD KL, RUDRA R, HORSFALL LU, HOSSAIN F, WILLIAMS S, et al. Multimorbidity and polypharmacy in diabetic patients with NAFLD: Implications for disease severity and management. Medicine (Baltimore). 2017; 96(26):e6761.
- 16. CALDERON-LARRANAGA A, GIMENO-FELIU LA, GONZALES-RUBIO F, POBLADOR-PLOU B, LAILA-SAN JOSE M, ABAD-DIEZ JM, et al. Polypharmacy patterns: unravelling systematic associations between prescribed medications. PLoS One. 2013; 8(12):e84967.
- 17. MASNOON A, SHAKIB S, KALISCH-ELLETT L, CAUGHEY GE. What is polypharmacy? A systematic review of definitions. BMC Geriatrics 2017; 17:230.
- 18. BEUSCART JB, PETIT S, GAUTIER S, WIERRE P, BALCAEN T, LEFEBVRE JM, et al. Polypharmacy in older patients: identifying the need for support by a community pharmacist. BMC Geriatrics 2019; 19(1):277.